DelveInsight’s “Biliary Tract Cancer (BTC) Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Biliary tract cancers Overview:
Biliary tract cancers (BTC) constitute epithelial malignancies of the biliary tree and include the following: Gallbladder cancer (GBC) and Cholangiocarcinoma (CCA). CCA is further divided into intra-hepatic CCA, perihilar (Klatskin’s tumor), and distal CCA.
Some of the key takeaways from Biliary Tract Cancer market report are:
- Biliary Tract Cancer market size was USD 553 million which is expected to rise during the study period (2019–2032).
- Biliary Tract Cancer companies working in the market are Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
- The total Biliary Tract Cancer market size by therapies for early stage disease in the year 2021 was USD 44.84 million which is expected to grow during the study period (2019-2032) in the 7MM.
To know in detail about the Biliary Tract Cancer market and epidemiology trends, click here: Biliary Tract Cancer Market Insight
Biliary Tract Cancer (BTC), also known as Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation.
The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect gall bladder.
Scope of the Biliary Tract Cancer market report:
- The report covers the descriptive overview of Biliary Tract Cancers (BTCs), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Biliary Tract Cancers (BTCs) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Biliary Tract Cancers (BTCs) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Biliary Tract Cancers (BTCs) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Biliary Tract Cancers (BTCs) market
To know more about the Biliary Tract Cancer market report offerings, click here: Biliary Tract Cancer Market Outlook
Biliary Tract Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted Biliary Tract Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Biliary Tract Cancer Epidemiology Segmentation:
The Biliary Tract Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Biliary Tract Cancer
- Prevalent Cases of Biliary Tract Cancer by severity
- Gender-specific Prevalence of Biliary Tract Cancer
- Diagnosed Cases of Biliary Tract Cancer
Key Biliary Tract Cancer Market Players:
Biliary Tract Cancer companies working in the market are Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
To know about the Biliary Tract Cancer companies and pipeline drugs, click here: Biliary Tract Cancer Therapies
Biliary Tract Cancer Drugs:
Some of the Biliary Tract Cancer therapies covered in the report are Ivosidenib, Pemigatinib, Melphalan Hydrochloride, Infigratinib, Acelarin, and Many Others.
Scope of the Biliary Tract Cancer Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Biliary Tract Cancer Companies: Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
- Key Biliary Tract Cancer Therapies: Ivosidenib, Pemigatinib, Melphalan Hydrochloride, Infigratinib, Acelarin, and Many Others.
- Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
- Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Biliary Tract Cancer Unmet Needs, KOL’s views, Analyst’s views, Biliary Tract Cancer Market Access and Reimbursement
Request a sample to know more about the recent developments in Biliary Tract Cancer treatment landscape @ Biliary Tract Cancer Clinical trials
Table of Contents:
1. Key Insights
2. Executive Summary of Biliary Tract Cancers (BTCs)
3. Competitive Intelligence Analysis for Biliary Tract Cancers (BTCs)
4. Biliary Tract Cancers (BTCs): Market Overview at a Glance
5. Biliary Tract Cancers (BTCs): Disease Background and Overview
6. Patient Journey
7. Biliary Tract Cancers (BTCs) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Biliary Tract Cancers (BTCs) Treatment
11. Marketed Products
12. Emerging Therapies
13. Biliary Tract Cancers (BTCs): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Biliary Tract Cancers (BTCs)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request a free sample report of Biliary Tract Cancer market to get deep insights into Biliary Tract Cancer unmet needs, drivers and barriers, KOL Views and SWOT Analysis @ Biliary Tract Cancer Market Dynamics
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting